

Special Issue

Mesothelioma: Diagnosis and Therapy

Message from the Guest Editor

Malignant mesothelioma is a rare incurable cancer that is predominantly related to asbestos exposure. There have been numerous advances in this field, including innovations in diagnostics, the development of enhanced staging and immunotherapy treatment, and novel evidence regarding surgical treatments and intrapleural therapy. This Special Issue therefore welcomes the submission of articles related to these topics. We are pleased to invite you to contribute to this Special Issue on mesothelioma with original research articles and reviews. The research included in this Special Issue may present updated diagnostic methods, novel treatment options and debates around surgical treatment. I look forward to receiving your contributions.

Guest Editor

Dr. Avinash Aujayeb

1. Respiratory Medicine Department, Northumbria Healthcare NHS Foundation Trust, Cramlington NE22 9EH, UK
2. Department of Respiratory Medicine, North Tyneside General Hospital, North Tyneside, Newcastle NE298NH, UK

Deadline for manuscript submissions

closed (30 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/215674

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)